IPA has entered a strategic partnership with Ribopro aiming to transform therapeutic antibody discovery and development.

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

Eli Lilly has announced plans to expand its domestic medicine production in the US with four new pharmaceutical manufacturing ...

The surge in demand for radiopharmaecuticals, the potential affect of Trump's tariffs on the clinical trials space, ensuring ...

The Phase III trial met the primary and secondary endpoints of reducing tics in children and adult patients with Tourette ...

With a potential buyer not working out, Idorsia has adjusted an existing partnership and restructured bonds to raise cash.

RedHill has signed an exclusive licensing agreement with Hyloris for the global development and commercialisation of RHB-102 ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Grin Therapeutics’ radiprodil.

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.